Eli Lilly and Company
礼来
Eli Lilly and Company is a global pharmaceutical firm that appears in elsewhere's corpus mainly through two distinct lenses: as a drug developer with direct R&D partnerships, and as the corporate parent of an independent China-focused venture arm.
On the operational side, Lilly has collaborated with Chinese 3D-printed drug startup Triastek on product and technology partnerships, alongside other multinationals like Merck and Boehringer Ingelheim . Separately, Lilly Asia Ventures spun out from the company's internal venture unit in 2011 to become one of the earliest and most active biotech-focused investors in China's innovation market, serving as both a financial vehicle and a strategic intelligence source for the parent company's pipeline . The fund is described in a 2023 暗涌Waves mapping of China's industrial investment landscape as a "life sciences and healthcare CVC with leadership status" in the sector .
The corpus does not contain details on Lilly's founding date, headquarters, market cap, or therapeutic focus areas beyond these China-facing activities.
AI-generated — may contain errors, please verify.
Coverage
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
"Zhongsheng Quanpeptide" Raises Over 300 Million Yuan in Series C Funding to Accelerate Global Expansion of Peptide-Based Innovative Drugs
It has secured multiple international partnerships with MNCs including Novartis and Eli Lilly and Company.
AI for Science Investment and Entrepreneurship: Where Are the Opportunities in the Next Decade?
"That failed data is valuable."
Innovation Often Happens Where No One Has Gone Before | 5Y News Monthly
The big news from last month.
Interview with RayzeBio: Two Funding Rounds in Six Months, How the Surging "Radiopharma" Sector Is Transforming Cancer Treatment | Gaorong Ventures
Accelerating on the "fast track" of TRT therapy.
Over $1.2 Billion in Total Value: Triastek Announces First-Ever Technology Platform International Collaboration in Chinese Pharmaceutical History with BioNTech | Yunqi Capital
Empowering Digital Transformation in Pharmaceutical Development
The Truth About Weight Loss, and Innovation Opportunities | FreeS Fund Report 36
Every unique you deserves a healthier, more vibrant body.
"Triastek" Closes 150 Million Yuan Pre-C Round to Accelerate Commercialization of 3D-Printed Drugs | Yunqi Capital
Pioneering a New Era of Intelligent Drug Discovery
How Can a "3D Printer" Boost Productivity in the Pharmaceutical Industry? | The B-Side of Entrepreneurship
Take the hard, meaningful path
June, the World's Childhood | 5Y News Monthly
The big news from last month.
A Playbook for Billion-Dollar Drug Development: Navigating Uncharted Waters and Making Landfall | Ronghui
From Prozac to Gleevec — how to persevere on the long and winding road.
